

20071018 10531801

Prepared by RICHARD A. HOUGHTLING, Ph.D.

Date of Search:

18 October 2007 at 9:17

Strategy:

(FILE 'HOME' ENTERED AT 15:13:37 ON 18 OCT 2007)

FILE 'REGISTRY' ENTERED AT 15:13:58 ON 18 OCT 2007

L1 1 S 220991-20-8/RN
L2 SCREEN 2076
L3 STRUCTURE UPLOADED
L4 QUE L3 AND L2
L5 12 S L3 SSS SAM
L6 92 S L3 SSS FULL

FILE 'CAPLUS, USPATFULL' ENTERED AT 15:28:06 ON 18 OCT 2007

FILE 'REGISTRY' ENTERED AT 15:31:08 ON 18 OCT 2007

L7 1 S L1 SSS SAM
L8 STRUCTURE UPLOADED
L9 QUE L8
L10 8 S L8 SSS SAM
L11 84 S L8 SSS FULL
L12 84 S L11 NOT (AYS OR CCS OR IDS OR MAN OR PMS)/CI

FILE 'CAPLUS, IMSDRUGNEWS, USPATFULL, PROUSDDR, PHAR' ENTERED AT
15:45:53
ON 18 OCT 2007

L13 493 S L12
E INFLAMMATION/CT
E INFLAMMATION (L) PAIN
E INFLAMMATION (L) PAIN/CT
E INFLAMMATORY (L) PAIN/CT
E INFLAMMAT???
E NOCICEPTI?/CT
L14 28457 S PAIN/CT
E PAIN CT
E PAIN/CT
E PAIN (L) NOCICEPTIVE/CT
L15 10070 S PAIN (L) NEUROPATHIC PAIN
E PAIN (L) MUSCLE
E PAIN (L) (MUSCLE OR MUSCULAR OR MUSCULATURE)/CT
E E98+ALL/CT
E E98+ALL
E E147+ALL

FILE 'REGISTRY' ENTERED AT 16:05:59 ON 18 OCT 2007

L16 STRUCTURE UPLOADED
L17 QUE L16
L18 1 S L16 SSS SAM
L19 116 S L16 SSS FULL

FILE 'CAPLUS, USPATFULL, IMSDRUGNEWS, PROUSDDR, PHAR' ENTERED AT
16:09:41
ON 18 OCT 2007

L20 1347 S L19
L21 20122 S (L15 OR (INFLAMMAT? AND L14) OR (NOCICEPTION AND L14))
L22 80 S L20 AND L21

L23 100 S L13 AND L21
L24 3 S L22 AND L23

Update Info:

REGISTRY

STRUCTURE FILE UPDATES: 17 OCT 2007 HIGHEST RN 950885-37-7

DICTIONARY FILE UPDATES: 17 OCT 2007 HIGHEST RN 950885-37-7

REGISTRY

STRUCTURE FILE UPDATES: 17 OCT 2007 HIGHEST RN 950885-37-7

DICTIONARY FILE UPDATES: 17 OCT 2007 HIGHEST RN 950885-37-7

REGISTRY

STRUCTURE FILE UPDATES: 17 OCT 2007 HIGHEST RN 950885-37-7

DICTIONARY FILE UPDATES: 17 OCT 2007 HIGHEST RN 950885-37-7

REGISTRY

STRUCTURE FILE UPDATES: 17 OCT 2007 HIGHEST RN 950885-37-7

DICTIONARY FILE UPDATES: 17 OCT 2007 HIGHEST RN 950885-37-7

Cost:

1058.88

Comments:

ANSWER SUMMARY

L22 ANSWER 38 OF 80 CAPLUS

Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain; 2004:372884 CAPLUS

L22 ANSWER 43 OF 80 CAPLUS

Method of treatment of persistent pain by inhibiting mediators of inflammation; 2004:162447 CAPLUS

L22 ANSWER 56 OF 80 USPATFULL on STN

Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain; 2007:184703 USPATFULL

L22 ANSWER 77 OF 80 USPATFULL on STN

Formulations of adenosine a1 agonists; 2003:11138 USPATFULL

L22 ANSWER 58 OF 80 USPATFULL on STN

Combination therapy for pain in painful diabetic neuropathy; 2007:49143 USPATFULL

L22 ANSWER 59 OF 80 USPATFULL on STN

Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep; 2006:315875 USPATFULL

L22 ANSWER 60 OF 80 USPATFULL on STN

Substituted indole compounds having NOS inhibitory activity; 2006:302361 USPATFULL

L22 ANSWER 61 OF 80 USPATFULL on STN

Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use; 2006:295576 USPATFULL

L22 ANSWER 62 OF 80 USPATFULL on STN

Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use; 2006:295575 USPATFULL

L22 ANSWER 63 OF 80 USPATFULL on STN

Use of r-10-hydroxy-10,11-dihydro-carbamazepine in neuropathic pain; 2006:196211 USPATFULL

L23 ANSWER 34 OF 100 CAPLUS

Pharmaceutical compositions containing a cyclooxygenase-2 inhibitor and a corticosteroid; 2004:927167 CAPLUS

L23 ANSWER 65 OF 100 USPATFULL on STN

Carboxylic acid peri-substituted bicyclics for occlusive artery disease; 2006:167844 USPATFULL

L23 ANSWER 78 OF 100 USPATFULL on STN

Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders; 2005:82076 USPATFULL

L23 ANSWER 89 OF 100 USPATFULL on STN

Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use; 2004:95444 USPATFULL

L23 ANSWER 95 OF 100 USPATFULL on STN

Combinations of a cyclooxygenase-2 selective inhibitor and a TNFalpha antagonist and therapeutic uses therefor; 2003:225250 USPATFULL

L23 ANSWER 96 OF 100 USPATFULL on STN

Drug mixture with enhanced dissolution rate; 2003:206914 USPATFULL

L23 ANSWER 97 OF 100 USPATFULL on STN

Method for the treatment and prevention of pain and inflammation with glucosamine and a cyclooxygenase-2 selective inhibitor and compositions therefor; 2003:166560

USPATFULL

L23 ANSWER 98 OF 100 USPATFULL on STN

Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate; 2003:166558 USPATFULL

L23 ANSWER 99 OF 100 USPATFULL on STN

Use of cox-2 inhibitors as gastroprokinetics; 2003:30948 USPATFULL

L23 ANSWER 100 OF 100 USPATFULL on STN

Formulations of adenosine a1 agonists; 2003:4089 USPATFULL

=> FILE REGISTRY

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 09:17:57 ON 18 OCT 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 OCT 2007 HIGHEST RN 950885-37-7

DICTIONARY FILE UPDATES: 17 OCT 2007 HIGHEST RN 950885-37-7



New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>



chain nodes :

22

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

ring/chain nodes :

16 17 18 19

ring/chain bonds :

11-16 16-17 16-18

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-11 7-8 8-9 9-10 9-12 10-11 10-15 12-13 13-14 14-15

exact/norm bonds :

5-7 6-11 7-8 8-9 10-11 11-16 16-17 16-18

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-12 10-15 12-13 13-14 14-15

G1: [*1], [*2]

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS
22:CLASS

=> file registry

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

2.70

2.91

FILE 'REGISTRY' ENTERED AT 09:21:38 ON 18 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 17 OCT 2007 HIGHEST RN 950885-37-7
DICTIONARY FILE UPDATES: 17 OCT 2007 HIGHEST RN 950885-37-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> file registry

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 15:13:58 ON 18 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 17 OCT 2007 HIGHEST RN 950885-37-7
DICTIONARY FILE UPDATES: 17 OCT 2007 HIGHEST RN 950885-37-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information

on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>



chain nodes :

16

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12

ring/chain nodes :

13 15 21 22 24 25 26 28

chain bonds :

15-16

ring/chain bonds :

3-28 5-15 6-13 7-25 8-21 9-24 10-13 11-26 12-22

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

exact/norm bonds :

3-28 5-15 6-13 7-25 8-21 9-24 10-13 11-26 12-22

exact bonds :

15-16

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

G1:H,F

G2:Cl,F

G3:CH₃,Et,MeO,EtO,H,Cl,F,OH

G4:Cl,F,CH₃,CF₃

G5:CH₃,Et

Hydrogen count :

13:>= minimum 1

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 15:CLASS 16:CLASS 21:CLASS 22:CLASS 24:CLASS 25:CLASS
26:CLASS 28:CLASS

=> FILE CAPLUS USPATFULL

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE

ENTRY

184.40

TOTAL

SESSION

184.61

FILE 'CAPLUS' ENTERED AT 15:28:06 ON 18 OCT 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:28:06 ON 18 OCT 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> FILE REGISTRY
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	7.83	192.44

FILE 'REGISTRY' ENTERED AT 15:31:08 ON 18 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 17 OCT 2007 HIGHEST RN 950885-37-7
DICTIONARY FILE UPDATES: 17 OCT 2007 HIGHEST RN 950885-37-7


New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>



chain nodes :
1 2 4 6
ring nodes :
7 8 9 10 11 12 13 14 15 16 17 18
ring/chain nodes :
3 5
chain bonds :
1-2 2-7 4-8 4-13 6-12
ring/chain bonds :
3-14 5-15
ring bonds :
7-8 7-10 8-9 9-11 10-12 11-12 13-14 13-15 14-16 15-17 16-18 17-18
exact/norm bonds :
3-14 4-8 4-13 5-15
exact bonds :
1-2 2-7 6-12
normalized bonds :
7-8 7-10 8-9 9-11 10-12 11-12 13-14 13-15 14-16 15-17 16-18 17-18

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS

=> FILE CAPLUS IMSDRUGNEWS USPATFULL PROUSDDR PHAR		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	396.04	588.48

FILE 'CAPLUS' ENTERED AT 15:45:53 ON 18 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'IMSDRUGNEWS' ENTERED AT 15:45:53 ON 18 OCT 2007
COPYRIGHT (C) 2007 IMSWORLD Publications Ltd

FILE 'USPATFULL' ENTERED AT 15:45:53 ON 18 OCT 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PROUSDDR' ENTERED AT 15:45:53 ON 18 OCT 2007
COPYRIGHT (C) 2007 Prous Science

FILE 'PHAR' ENTERED AT 15:45:53 ON 18 OCT 2007
COPYRIGHT (C) 2007 Informa UK Ltd.

=> FILE REGISTRY		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	85.60	674.08

FILE 'REGISTRY' ENTERED AT 16:05:59 ON 18 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 17 OCT 2007 HIGHEST RN 950885-37-7
DICTIONARY FILE UPDATES: 17 OCT 2007 HIGHEST RN 950885-37-7


New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>



ring nodes :
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
 ring/chain nodes :
 16 17 18 19
 ring/chain bonds :
 1-17 4-16 17-18 17-19
 ring bonds :
 1-2 1-7 2-3 2-8 3-4 3-11 4-5 5-6 6-7 6-12 7-15 8-9 9-10 10-11 12-13 13-14 14-15
 exact/norm bonds :
 1-2 1-7 1-17 3-4 4-16 5-6 17-18 17-19
 normalized bonds :
 2-3 2-8 3-11 6-7 6-12 7-15 8-9 9-10 10-11 12-13 13-14 14-15

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS
 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS

=> FILE CAPLUS USPATFULL IMSDRUGNEWS PROUSDDR PHAR		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	174.35	848.43

FILE 'CAPLUS' ENTERED AT 16:09:41 ON 18 OCT 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:09:41 ON 18 OCT 2007
 CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'IMSDRUGNEWS' ENTERED AT 16:09:41 ON 18 OCT 2007
 COPYRIGHT (C) 2007 IMSWORLD Publications Ltd

FILE 'PROUSDDR' ENTERED AT 16:09:41 ON 18 OCT 2007
 COPYRIGHT (C) 2007 Prous Science

FILE 'PHAR' ENTERED AT 16:09:41 ON 18 OCT 2007
 COPYRIGHT (C) 2007 Informa UK Ltd.

L22 ANSWER 38 OF 80 CAPLUS COPYRIGHT 2007 ACS on STN
 Title

Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management
 and/or modification of pain

Accession Number
 2004:372884 CAPLUS Full-text

Document Number
 140:368721

Author/Inventor

Zeldis, Jerome B.; Faleck, Herbert; Manning, Donald C.
Patent Assignee/Corporate Source
USA

Source

U.S. Pat. Appl. Publ., 35 pp. CODEN: USXXCO

Document Type

Patent

Language

English

Family Accession Number Count

1

Patent Information

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004087642	A1	20040506	US 2003-693793	20031023
CA 2503616	A1	20040513	CA 2003-2503616	20031024
WO 2004039325	A2	20040513	WO 2003-US34006	20031024
WO 2004039325	A3	20041111		
AU 2003284980	A1	20040525	AU 2003-284980	20031024
EP 1553951	A2	20050720	EP 2003-779300	20031024
BR 2003015573	A	20050830	BR 2003-15573	20031024
CN 1732004	A	20060208	CN 2003-80107549	20031024
JP 2006511495	T	20060406	JP 2004-548497	20031024
MX 2005PA04180	A	20050920	MX 2005-PA4180	20050420

Abstract

The present invention relates to methods for treating, preventing, managing and/or modifying pain, comprising administering an effective amount of a JNK inhibitor to a patient in need thereof. Specific embodiments encompass the administration of a JNK inhibitor, alone or in combination with a second active agent and/or surgery or phys. therapy. Pharmaceutical compns., single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. 5-Aminoanthra[9,1- cd]isothiazol-6-one inhibited JNK2 and JNK3, inhibited IL-2 production in Jurkat T-cells, and protected rat ventral mesencephalon neurons from the toxic effects of 6-hydroxydopamine.

Controlled or Index Terms

28721-07-5, Oxcarbazepine

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);

THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(as second active agent; JNK inhibitor for treatment, prevention, management and/or modification of pain)

L22 ANSWER 43 OF 80 CAPLUS COPYRIGHT 2007 ACS on STN
Title

Method of treatment of persistent pain by inhibiting mediators of inflammation

Accession Number

2004:162447 CAPLUS [Full-text](#)

Document Number

140:193061

Author/Inventor

Omoigui, Osemwota

Patent Assignee/Corporate Source

USA

Source

U.S. Pat. Appl. Publ., 14 pp. CODEN: USXXCO

Document Type

Patent

Language

English

Family Accession Number Count

6

Patent Information

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004038874	A1	20040226	US 2002-224743	20020822
US 2005152905	A1	20050714	US 2005-58371	20050216
US 2006275294	A1	20061207	US 2006-279239	20060410

102e

Abstract

This invention relates to a method for treating persistent pain disorders by inhibiting the biochem. mediators of inflammation in a subject comprising administering to said subject a therapeutically effective dosage of said inhibitor. Said process for treating persistent pain disorders is based on Sota Omoigui's Law, which states: The origin of all pain is inflammation and the inflammatory response. Biochem. mediators of inflammation that are targeted for inhibition include but are not limited to: prostaglandin, nitric oxide, tumor necrosis factor alpha, interleukin 1-alpha, interleukin 1-beta, interleukin-4, Interleukin-6 and interleukin-8, histamine and serotonin, substance P, Matrix Metallo-Proteinase, calcitonin gene-related peptide, vasoactive intestinal peptide as well as the potent inflammatory mediator peptide proteins neurokinin A, bradykinin, kallidin and T-kinin.

Controlled or Index Terms

28721-07-5, Oxcarbazepine

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);

THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(as nitric oxide inhibitor; persistent pain treatment by inhibiting mediators of inflammation)

L22 ANSWER 56 OF 80 USPATFULL on STN**Title**

Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain

Accession Number2007:184703 USPATFULL Full-text**Author/Inventor**

Zeldis, Jerome B., Princeton, NJ, UNITED STATES Faleck, Herbert, West Orange, NJ, UNITED STATES

Manning, Donald C., Bloomsbury, NJ, UNITED STATES

Document Type

Utility

Patent Information

PATENT NO.	KIND	DATE
US 2007161696	A1	20070712

Abstract

Methods of treating, preventing, modifying and managing various types of pain are disclosed. Specific

methods comprise the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery, psychological or physical therapy. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Controlled or Index Terms

28721-07-5, Oxcarbazepine
(methods of using and compns. comprising immunomodulatory compds. for treatment, modification and management of pain)

L22 ANSWER 77 OF 80 USPATFULL on STN

Title

Formulations of adenosine a1 agonists

Accession Number

2003:11138 USPATFULL [Full-text](#)

Author/Inventor

Bountra, Charanjit, Stevenage, UNITED KINGDOM Clayton, Nicholas Maughan, Stevenage, UNITED KINGDOM Naylor, Alan, Stevenage, UNITED KINGDOM

Document Type

Utility

Patent Information

PATENT NO.	KIND	DATE
US 2003008842	A1	20030109

Abstract

The present invention provides a method of treating conditions associated with pain and alleviating the symptoms associated therewith which comprises administering to a mammal, including man, an adenosine A1 agonist or a physiologically acceptable salt or solvate thereof and a sodium channel blocker or a physiologically acceptable salt or solvate thereof. The present invention also provides pharmaceutical formulations and patient packs comprising said combinations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Controlled or Index Terms

28721-07-5, Oxcarbazepine
(formulations of adenosine A1 agonists)

L22 ANSWER 58 OF 80 USPATFULL on STN

Title

Combination therapy for pain in painful diabetic neuropathy

Accession Number

2007:49143 USPATFULL [Full-text](#)

Author/Inventor

Rauschkolb-Löffler, Christine, Solingen, GERMANY, FEDERAL REPUBLIC OF Koch, Brigitte, Monheim, GERMANY, FEDERAL REPUBLIC OF Stohr, Thomas, Monheim, GERMANY, FEDERAL REPUBLIC OF

Patent Assignee/Corporate Source

SRZ Properties, Inc., Wilmington, DE, UNITED STATES (non-U.S. corporation)

NUMBER KIND DATE -----

Document Type

Utility

Patent Information

PATENT NO.	KIND	DATE
US 2007042969	A1	20070222

Abstract

A method for treating pain in painful diabetic neuropathy comprises administering in combination a first agent that comprises a compound as defined herein, illustratively lacosamide, and a second agent effective to provide enhanced treatment of pain, by comparison with the first agent alone. The second agent illustratively comprises an analgesic, an anticonvulsant, an antidepressant or an NMDA receptor antagonist.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Controlled or Index Terms

28721-07-5, Oxcarbazepine

(lacosamide or other amide compound combination with second agent for treatment of pain in painful diabetic neuropathy)

L22 ANSWER 59 OF 80 USPATFULL on STN

Title

Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep

Accession Number

2006:315875 USPATFULL [Full-text](#)

Author/Inventor

Manning, Donald, Bloomsbury, NJ, UNITED STATES

NUMBER KIND DATE -----

Document Type

Utility

Patent Information

PATENT NO.	KIND	DATE
US 2006270658	A1	20061130

Abstract

The present invention provides for novel uses of the carbamazepine derivative of formula (I) ##STR1## and its pharmaceutically acceptable salts, in particular an improved regimen for the administration of the carbamazepine derivative of formula (I) and the pharmaceutically acceptable salts thereof for the treatment of patients suffering from pin, in particular neuropathic pain, and the improvement of sleep; the use of oxcarbazepine for the manufacture of a pharmaceutical composition for the treatment of pain or the manufacture of a pharmaceutical composition for the improvement of sleep in human patients suffering from chronic pain; pharmaceutical composition comprising oxcarbazepine as sole active ingredient for the treatment of pain or for the improvement of sleep in human patients suffering from chronic pain and to packages comprising a pharmaceutical composition comprising as sole active ingredient oxcarbazepine together with instructions for the treatment of pain or together with instructions for improvement of sleep in human patients suffering from chronic pain.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Controlled or Index Terms

28721-07-5, Trileptal

(oxcarbazepine for treatment of pain, including diabetic neuropathic pain, and improvement of sleep)

L22 ANSWER 60 OF 80 USPATFULL on STN

Title

Substituted indole compounds having NOS inhibitory activity

Accession Number

2006:302361 USPATFULL Full-text

Author/Inventor

Maddaford, Shawn, Mississauga, CANADA Ramnauth, Jailall, Brampton, CANADA Rakhit, Suman, Mississauga, CANADA Patman, Joanne, Mississauga, CANADA Renton, Paul, Toronto, CANADA Annedi, Subhash C., Mississauga, CANADA

NUMBER KIND DATE -----

Document Type

Utility

Patent Information

PATENT NO.	KIND	DATE
US 2006258721	A1	20061116

Abstract

The present invention features inhibitors of nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing conditions such as, for example, stroke, reperfusion injury, neurodegeneration, head trauma, CABG, migraine headache with and without aura, migraine with allodynia, central post-stroke pain (CPSP), neuropathic pain, morphine/opioid induced tolerance and hyperalgesia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Controlled or Index Terms

28721-07-5, Oxcarbazepine
(preparation of substituted indole compds. with NOS inhibitory activity
useful as therapeutic agents)

L22 ANSWER 61 OF 80 USPATFULL on STN

Title

Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use

Accession Number

2006:295576 USPATFULL Full-text

Author/Inventor

Almeida, Jose Luis de, Arouca, PORTUGAL Araujo Soares Da Silva, Patricio Manuel Vieira, Porto, PORTUGAL

Patent Assignee/Corporate Source

Portela & C.A., S.A. (non-U.S. corporation)

NUMBER KIND DATE -----

Document Type

Utility

Patent Information

PATENT NO.	KIND	DATE
US 2006252746	A1	20061109

Abstract

The present disclosure relates to the treatment of various diseases and conditions with eslicarbazepine acetate. The present disclosure also relates to the use of eslicarbazepine acetate in a method for reducing or decreasing epileptic seizures in a patient. The present disclosure also relates to a method for increasing the exposure to eslicarbazepine in a patient. The present disclosure also relates to a method of preparing a pharmaceutical composition comprising eslicarbazepine acetate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Controlled or Index Terms

104746-04-5, Eslicarbazepine
(eslicarbazepine acetate pharmaceutical compns. for treatment of
epilepsy and other conditions)
236395-14-5
(eslicarbazepine acetate pharmaceutical compns. for treatment of
epilepsy and other conditions)
29331-92-8, BIA 2-005 104746-03-4
(eslicarbazepine acetate pharmaceutical compns. for treatment of
epilepsy and other conditions)

L22 ANSWER 62 OF 80 USPATFULL on STN

Title

Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use

Accession Number

2006:295575 USPATFULL [Full-text](#)

Author/Inventor

Almeida, Jose Luis de, Arouca, PORTUGAL Soares-Da-Silva, Patricio Manuel Vieira Araujo, Porto,
PORTUGAL

NUMBER KIND DATE -----

Document Type

Utility

Patent Information

PATENT NO.	KIND	DATE
US 2006252745	A1	20061109

Abstract

The present disclosure relates to the treatment of various diseases and conditions with eslicarbazepine acetate. The present disclosure also relates to the use of eslicarbazepine acetate in a method for reducing or decreasing epileptic seizures in a patient. The present disclosure also relates to a method for increasing the exposure to eslicarbazepine in a patient. The present disclosure also relates to a method of preparing a pharmaceutical composition comprising eslicarbazepine acetate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Controlled or Index Terms

104746-04-5, Eslicarbazepine
(eslicarbazepine acetate pharmaceutical compns. for treatment of
epilepsy and other conditions)
236395-14-5
(eslicarbazepine acetate pharmaceutical compns. for treatment of
epilepsy and other conditions)
29331-92-8, BIA 2-005 104746-03-4
(eslicarbazepine acetate pharmaceutical compns. for treatment of
epilepsy and other conditions)

L22 ANSWER 63 OF 80 USPATFULL on STN

Title

Use of r-10-hydroxy-10,11-dihydro-carbamazepine in neuropathic pain

Accession Number

2006:196211 USPATFULL [Full-text](#)

Author/Inventor

Fox, Alyson, London, UNITED KINGDOM Bevan, Stuart, London, UNITED KINGDOM

NUMBER KIND DATE -----

Document Type

Utility
Patent Information

PATENT NO.	KIND	DATE
US 2006166967	A1	20060727

Abstract

The present invention relates to the use of a mixture of the enantiomers of a compound of Formula (I) or of pharmaceutically acceptable salts of said enantiomers consisting of at least 55% of the R-enantiomer, most preferably of at least 98% of the R-enantiomer, and not more than 45 % of the S-enantiomer, most preferably not more than 2% of the S-enantiomer, for the manufacture of a pharmaceutical composition for the treatment of neuropathic pain; to a method for the treatment of neuropathic pain; and to a pharmaceutical composition comprising as active agent a mixture of the enantiomers of the compound of formula I or pharmaceutically acceptable salts of said enantiomers consisting of at least 55% of the R-enantiomer and not more than 45% of the S-enantiomer. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Controlled or Index Terms

104746-04-5P
(hydroxydihydrocarbamazepine enantiomers for treatment of neuropathic pain)
104746-03-4P
(hydroxydihydrocarbamazepine enantiomers for treatment of neuropathic pain)
29331-92-8
(hydroxydihydrocarbamazepine enantiomers for treatment of neuropathic pain)
28721-07-5
(hydroxydihydrocarbamazepine enantiomers for treatment of neuropathic pain)

L23 ANSWER 34 OF 100 CAPLUS COPYRIGHT 2007 ACS on STN

Title

Pharmaceutical compositions containing a cyclooxygenase-2 inhibitor and a corticosteroid

Accession Number

2004:927167 CAPLUS Full-text

Document Number

141:400902

Author/Inventor

Seibert, Karen

Patent Assignee/Corporate Source

Pharmacia Corporation, USA

Source

PCT Int. Appl., 182 pp. CODEN: PIXXD2

Document Type

Patent

Language

English

Family Accession Number Count

1

Patent Information

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004094373	A2	20041104	WO 2004-US8319	20040318

WO 2004094373	A3	20060216		
US 2004220155	A1	20041104	US 2004-803145	20040317
CA 2520360	A1	20041104	CA 2004-2520360	20040318
EP 1611095	A2	20060104	EP 2004-759655	20040318
BR 2004008944	A	20060704	BR 2004-8944	20040318
JP 2006521356	T	20060921	JP 2006-507329	20040318

Abstract

A method is described for providing a steroid-sparing benefit to a subject that is in need of, or presently receiving, a corticosteroid, the method comprising administering to the subject a cyclooxygenase-2 inhibitor in combination with a corticosteroid. Therapeutic compns., pharmaceutical compns. and kits that are useful for implementing the present method are also described. Thus, a composition contained prednisone 10 and celecoxib 200 g.

Controlled or Index Terms

220991-20-8, Lumiracoxib

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. containing cyclooxygenase-2 inhibitor and corticosteroid)

L23 ANSWER 65 OF 100 USPATFULL on STN

Title

Carboxylic acid peri-substituted bicyclics for occlusive artery disease

Accession Number

2006:167844 USPATFULL [Full-text](#)

Author/Inventor

Singh, Jasbir, Naperville, IL, UNITED STATES Gurney, Mark, Grand Rapids, MI, UNITED STATES Hategan, Georgeta, Naperville, IL, UNITED STATES Yu, Peng, Lisle, IL, UNITED STATES Zembower, David, LaGrange, IL, UNITED STATES Zhou, Nian, Naperville, IL, UNITED STATES Polozov, Alexandre Mikhaylovich, Naperville, IL, UNITED STATES Zeller, Wayne Edward, Viroqua, WI, UNITED STATES

Patent Assignee/Corporate Source

deCODE Chemistry, Inc., Woodridge, IL, UNITED STATES (U.S. corporation)

Document Type

Utility

Patent Information

PATENT NO.	KIND	DATE
US 2006142355	A1	20060629

Abstract

Peri-substituted, fused bicyclic ring carboxylic acids useful for the treatment or prophylaxis of a prostaglandin-mediated disease or condition are disclosed. The compounds are of the general formula ##STR1## A representative example is: ##STR2##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Controlled or Index Terms

220991-20-8, Lumiracoxib

(preparation of carboxylic acid peri - substituted bicyclics and their prostanoid EP3 receptor binding activity for treatment of occlusive artery disease)

L23 ANSWER 78 OF 100 USPATFULL on STN

Title

Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders

Accession Number

2005:82076 USPATFULL [Full-text](#)

Author/Inventor

Stephenson, Diane T., Groton, CT, UNITED STATES Taylor, Duncan P., Bridgewater, NJ, UNITED STATES Arneric, Stephen P., Milan, MI, UNITED STATES

Patent Assignee/Corporate Source

Pharmacia Corporation (U.S. corporation)

Document Type

Utility

Patent Information

PATENT NO.	KIND	DATE
US 2005070524	A1	20050331

Abstract

The present invention provides compositions and methods for the treatment of central nervous system disorders or related conditions in a subject. More particularly, the invention provides a combination therapy for the treatment of seizures, or seizure disorders comprising the administration to a subject of an anticonvulsant agent in combination with a cyclooxygenase-2 selective inhibitor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Controlled or Index Terms

220991-20-8, Lumiracoxib

(cyclooxygenase-2 selective inhibitor-anticonvulsant agent combination for treatment of central nervous system disorders)

L23 ANSWER 89 OF 100 USPATFULL on STN

Title

Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use

Accession Number

2004:95444 USPATFULL [Full-text](#)

Author/Inventor

Letts, L. Gordon, Dover, MA, UNITED STATES Garvey, David S., Dover, MA, UNITED STATES

Document Type

Utility

Patent Information

PATENT NO.	KIND	DATE
US 2004072899	A1	20040415
US 7220749	B2	20070522

Abstract

The invention describes novel nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or, optionally, at least one therapeutic agent. The invention also provides novel compositions comprising at least one COX-2 selective inhibitor, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing;

for treating and/or preventing renal and/or respiratory toxicity; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors. The invention also provides novel kits comprising at least one COX-2 selective inhibitor optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention are preferably 2(2-((2-chloro-6-fluorophenyl)amino)5- methylphenyl)acetic acid and nitrosated derivatives thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Controlled or Index Terms

220991-20-8D, derivs.

(nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors)

L23 ANSWER 95 OF 100 USPATFULL on STN

Title

Combinations of a cyclooxygenase-2 selective inhibitor and a TNFalpha antagonist and therapeutic uses therefor

Accession Number

2003:225250 USPATFULL [Full-text](#)

Author/Inventor

Bennett, Dennis A., Wildwood, MO, UNITED STATES

Patent Assignee/Corporate Source

Pharmacia Corporation, St. Louis, MO, UNITED STATES (U.S. corporation)

Document Type

Utility

Patent Information

PATENT NO.	KIND	DATE
US 2003157061	A1	20030821

Abstract

A method for the prevention, treatment, or inhibition of pain, inflammation, or inflammation-related disorder and for the prevention, treatment, or inhibition of a cardiovascular disease or disorder in a subject that is in need of such prevention, treatment or inhibition, involves the administration to the subject of a cyclooxygenase-2 selective inhibitor or prodrug thereof and a TNF α antagonist. A method can also involve the treatment, prevention, or inhibition of cancer in a subject in need of such treatment, prevention, or inhibition, by administering to the subject a cyclooxygenase-2 selective inhibitor or prodrug thereof and a TNF α antagonist which is selected from the group consisting of a compound that affects the synthesis of TNF α , a compound that inhibits the binding of TNF α with a receptor specific for TNF α , and a compound that interferes with intracellular signaling triggered by TNF α binding with a receptor. Compositions, pharmaceutical compositions and kits that can be used with the methods are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Controlled or Index Terms

220991-20-8, COX 189

(combinations of a cyclooxygenase-2 selective inhibitor and a TNF- α antagonist and therapeutic uses for pain and inflammation)

L23 ANSWER 96 OF 100 USPATFULL on STN

Title

Drug mixture with enhanced dissolution rate

Accession Number

2003:206914 USPATFULL [Full-text](#)

Author/Inventor

Ewing, Gary D., Kalamazoo, MI, UNITED STATES Hawley, Michael, Kalamazoo, MI, UNITED STATES Coffey, Martin J., Portage, MI, UNITED STATES Price, Jeffrey E., Middlebury, IN, UNITED STATES

MacMillan, Stephen P., Newton, PA, UNITED STATES

Document Type

Utility

Patent Information

PATENT NO.	KIND	DATE
US 2003143271	A1	20030731

Abstract

A pharmaceutical composition comprises one or more discrete orally deliverable dosage forms, each comprising a poorly soluble coxib component in an amount effective when administered once daily for treatment or prevention of a COX-2 mediated disorder, an aspirin component in a cardioprotective effective amount when administered once daily, and at least one pharmaceutically acceptable excipient; the dosage forms having no substantial barrier to intimate commingling of the coxib and aspirin components. A method of simultaneously treating or preventing a COX-2 mediated disorder and providing cardioprotection comprises orally administering such a pharmaceutical composition to a subject in need thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Controlled or Index Terms

220991-20-8, Lumiracoxib

(cyclooxygenase-2 selective inhibitor-aspirin combination for treatment of pain, inflammation, and inflammation-related disorders)

L23 ANSWER 97 OF 100 USPATFULL on STN

Title

Method for the treatment and prevention of pain and inflammation with glucosamine and a cyclooxygenase-2 selective inhibitor and compositions therefor

Accession Number

2003:166560 USPATFULL [Full-text](#)

Author/Inventor

Pulaski, Steven P., Branchburg, NJ, UNITED STATES Kundel, Susan, Basel, SWITZERLAND

Patent Assignee/Corporate Source

Pharmacia Corporation, St. Louis, MO, 63167 (U.S. corporation)

Document Type

Utility

Patent Information

PATENT NO.	KIND	DATE
US 2003114418	A1	20030619

Abstract

A method of treating, preventing, or inhibiting pain, inflammation or inflammation-associated disorder in a subject in need of such treatment or prevention provides for treating the subject with glucosamine and a cyclooxygenase-2 selective inhibitor or prodrug thereof, wherein the amount of glucosamine and the amount of a cyclooxygenase-2 selective inhibitor or prodrug thereof together constitute a pain or inflammation suppressing treatment or prevention effective amount of the composition. Compositions and pharmaceutical compositions that contain glucosamine and a cyclooxygenase-2 selective inhibitor are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Controlled or Index Terms

220991-20-8, COX 189

(treatment and prevention of pain and inflammation with formulations containing cyclooxygenase-2 selective inhibitors and glucosamine)

L23 ANSWER 98 OF 100 USPATFULL on STN

Title

Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate

Accession Number

2003:166558 USPATFULL [Full-text](#)

Author/Inventor

Pulaski, Steven P., Branchburg, NJ, UNITED STATES Kundel, Susan, Basel, SWITZERLAND

Patent Assignee/Corporate Source

Pharmacia Corporation, St. Louis, MO (U.S. corporation)

Document Type

Utility

Patent Information

PATENT NO.	KIND	DATE
US 2003114416	A1	20030619

Abstract

A method of treating, preventing, or inhibiting pain, inflammation or inflammation-associated disorder in a subject in need of such treatment or prevention provides for treating the subject with chondroitin sulfate and a cyclooxygenase-2 selective inhibitor, or a prodrug thereof, wherein the amount of chondroitin sulfate and the amount of a cyclooxygenase-2 selective inhibitor or a pharmaceutically acceptable salt or prodrug thereof together constitute a pain or inflammation suppressing treatment or prevention effective amount. Glucosamine can optionally be present. Compositions that contain the combination of chondroitin sulfate and cyclooxygenase-2 selective inhibitor and, optionally, the glucosamine, are disclosed, as are pharmaceutical compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Controlled or Index Terms

220991-20-8, COX 189 220991-20-8D, COX 189, prodrug
derivs.

(COX 189; cyclooxygenase 2 inhibitor and chondroitin sulfate for
treatment and prevention of pain and inflammation)

L23 ANSWER 99 OF 100 USPATFULL on STN**Title**

Use of cox-2 inhibitors as gastroprokinetics

Accession Number

2003:30948 USPATFULL [Full-text](#)

Author/Inventor

Mangel, Allen Wayne, Chapel Hill, NC, UNITED STATES Naylor, Alan, Stevenage, UNITED KINGDOM

Document Type

Utility

Patent Information

PATENT NO.	KIND	DATE
US 2003022897	A1	20030130
US 6759413	B2	20040706

Abstract

The invention provides a COX-2 inhibitor or a pharmaceutically acceptable derivative thereof for use in the treatment of a disorder ameliorated by a gastroprokinetic.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Controlled or Index Terms

220991-20-8

(COX 189; cyclooxygenase-2 inhibitors as gastroprokinetic agents)
220991-20-8D, derivs.
(cyclooxygenase-2 inhibitors as gastroprokinetic agents)

L23 ANSWER 100 OF 100 USPATFULL on STN

Title

Formulations of adenosine a1 agonists

Accession Number

2003:4089 USPATFULL Full-text

Author/Inventor

Bountra, Charanjit, Stevenage, UNITED KINGDOM Clayton, Nicholas Maughan, Stevenage, UNITED KINGDOM Naylor, Alan, Stevenage, UNITED KINGDOM

Document Type

Utility

Patent Information

PATENT NO.	KIND	DATE
US 2003004128	A1	20030102

Abstract

The present invention provides a method of treating conditions associated with pain and alleviating the symptoms associated therewith which comprises administering to a mammal, including man, an adenosine A1 agonist or a physiologically acceptable salt or solvate thereof and an NSAID, e.g. a COX-2 inhibitor, or a physiologically acceptable salt or solvate thereof. The present invention also provides pharmaceutical formulations and patient packs comprising said combinations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Controlled or Index Terms

220991-20-8

(COX 189; formulations of adenosine A1 agonists)